Hepatitis C

doi:10.1016/B978-1-4557-4801-3.00156-9

Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth Edition)

Volume 2, 2015, Pages 1904-1927.e9

https://doi.org/10.1016/B978-1-4557-4801-3.00156-9 Get rights and content

First page preview

Click to open first page preview

View PDF

References (0)

Cited by (13)

Hepatitis C core antigen: Diagnosis and monitoring of patients infected with hepatitis C virus
2019, International Journal of Infectious Diseases
Citation Excerpt :
The global prevalence of people with hepatitis C virus (HCV) antibodies (anti-HCV-positive) is estimated to be 115 million, and 80 million of them have an active infection (anti-HCV-positive and HCV-RNA-positive) (WHO, 2016; Gower et al., 2014). Most HCV-infected individuals remain asymptomatic for decades and only 25% of them achieve spontaneous viral clearance, while 75% develop chronic infection (Forman and Valsamakis, 2015; Ray and Thomas, 2015). Around 10–20% of chronically infected patients develop liver cirrhosis or hepatocellular carcinoma (Ponziani et al., 2017).
New efficient strategies are needed for the assessment of active hepatitis C virus (HCV) infection. The aim of this study was to evaluate the ability of HCV core antigen (HCV-cAg) as a marker of active HCV infection in newly diagnosed patients, for treatment monitoring, and for the detection of therapeutic failure.
A prospective study was conducted at a regional reference hospital in Spain. HCV-cAg and viral load (RNA-HCV) were tested in plasma or serum samples from three patient groups: new diagnosis, treatment monitoring, and treatment failure. The treatment monitoring group was tested at the beginning of treatment, at 4 weeks post-initiation, at the end of treatment, and at 12 weeks post-treatment completion. The Architect HCV core antigen assay was performed for HCV-cAg testing, and viral load was quantified with the Cobas 6800 system.
A total of 303 samples from 124 patients were analyzed. Excellent correlation was seen between HCV-cAg and HCV-RNA (R² = 0.932). The optimal cut-off value was 3 fmol/l in the receiver operating characteristics curve analysis, and the area under the curve was 0.987 (95% confidence interval 0.972–1.000). HCV-cAg sensitivity and specificity were 97% and 95%, respectively. Most diverging results were observed in the treatment follow-up group.
HCV-cAg demonstrated good sensitivity and specificity as a marker for active HCV infection, new diagnosis, detection of antiviral therapeutic failure, and treatment monitoring.
In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2
2021, PLoS Pathogens
PROLIDASE: A Review from Discovery to its Role in Health and Disease
2021, Frontiers in Molecular Biosciences
HCV Infection in Thalassemia Syndromes and Hemoglobinopathies: New Perspectives
2020, Frontiers in Molecular Biosciences
Overview of direct-acting antiviral drugs and drug resistance of hepatitis C virus
2019, Methods in Molecular Biology
Does active hepatitis C virus infection increase the risk for infection due to Staphylococcus aureus?
2017, European Journal of Clinical Microbiology and Infectious Diseases

View all citing articles on Scopus

View full text

156 - Hepatitis C

First page preview